How are tinea capitis infections treated pharmacologically and what are distinguishing clinical features?

How are tinea capitis infections treated pharmacologically and what are distinguishing clinical features?

• A. Topical antifungals alone are sufficient.
• B. It presents with diffuse hair shedding without inflammation.
• C. Systemic antifungals such as terbinafine or griseofulvin; presents with scaly patches, broken hairs, and possible inflammation; requires systemic treatment.
• D. Antibiotics are the first-line therapy.

Answer: (C)

Tinea capitis requires systemic antifungal therapy because the fungus invades the hair shaft and follicles, not just the surface of the scalp. Topical antifungals alone can’t reach the organisms inside the hair, so they’re insufficient for eradicating the infection. The preferred pharmacologic approach uses systemic antifungals, most commonly terbinafine or griseofulvin. Terbinafine is a fungicidal agent that inhibits squalene epoxidase, leading to disruption of fungal cell membranes; it penetrates scalp hair well and is typically given for several weeks (often around six) in children. Griseofulvin interferes with fungal mitosis and has been a traditional choice, usually administered for a longer course (several weeks to a few months), and it tends to be effective against species like Microsporum. Clinically, tinea capitis presents with scaly patches on the scalp, broken hairs at the skin surface (giving a “black-dot” appearance), and alopecia. Inflammatory forms can occur, producing a boggy, tender mass called a kerion. These features help distinguish it from conditions that cause diffuse hair shedding without inflammation, which are not fungal infections, and from scenarios where topical therapy or antibiotics would be appropriate. So, systemic antifungals like terbinafine or griseofulvin are necessary to treat tinea capitis effectively, and the diagnosis is supported by scaly patches, broken hairs, and possible inflammatory signs.

Tinea capitis requires systemic antifungal therapy because the fungus invades the hair shaft and follicles, not just the surface of the scalp. Topical antifungals alone can’t reach the organisms inside the hair, so they’re insufficient for eradicating the infection.

The preferred pharmacologic approach uses systemic antifungals, most commonly terbinafine or griseofulvin. Terbinafine is a fungicidal agent that inhibits squalene epoxidase, leading to disruption of fungal cell membranes; it penetrates scalp hair well and is typically given for several weeks (often around six) in children. Griseofulvin interferes with fungal mitosis and has been a traditional choice, usually administered for a longer course (several weeks to a few months), and it tends to be effective against species like Microsporum.

Clinically, tinea capitis presents with scaly patches on the scalp, broken hairs at the skin surface (giving a “black-dot” appearance), and alopecia. Inflammatory forms can occur, producing a boggy, tender mass called a kerion. These features help distinguish it from conditions that cause diffuse hair shedding without inflammation, which are not fungal infections, and from scenarios where topical therapy or antibiotics would be appropriate.

So, systemic antifungals like terbinafine or griseofulvin are necessary to treat tinea capitis effectively, and the diagnosis is supported by scaly patches, broken hairs, and possible inflammatory signs.